Article and Video CATEGORIES
Here is the second of three cases covering issues in managing elderly and frail patients with lung cancer that I discussed with experts Paul J. Hesketh from Lahey Clinic and Karen Kelly from Kansas University Medical Center. Both major experts in lung cancer, they have a lot of experience and have been leaders in publishing on the understudied population of elderly and poor performance status patients with lung cancer. This particular case covers treatment options for a patient with unresectable stage III non-small cell lung cancer (NSCLC).
Here is the audio and video versions of the podcast, along with the figures and transcript.
[powerpress]
loc-adv-nsclc-in-frail-and-elderly-patients-hesketh-and-kelly-audio-podcast
loc-adv-nsclc-in-frail-and-elderly-patients-hesketh-and-kelly-transcript
loc-adv-nsclc-in-frail-and-elderly-patients-hesketh-and-kelly-figures
The third and final case will cover treating elderly/frail patients with advanced NSCLC.
This program was made possible by an educational grant from OSI Pharmaceuticals, who had no input in its content. We thank them for their support.
Please feel free to offer comments and raise questions in our
discussion forums.
Forum Discussions
Hi elysianfields and welcome to Grace. I'm sorry to hear about your father's progression.
Unfortunately, lepto remains a difficult area to treat. Recently FDA approved the combo Lazertinib and Amivantamab...
Hello Janine, thank you for your reply.
Do you happen to know whether it's common practice or if it's worth taking lazertinib without amivantamab? From all the articles I've come across...
Hi elysianfields,
That's not a question we can answer. It depends on the individual's health. I've linked the study comparing intravenous vs. IV infusions of the doublet lazertinib and amivantamab...
Recent Comments
That's…
That's beautiful Linda. Thank you,